With its „AlpVision COVID-19 Initiative“ launched today, AlpVision aims to support pharmaceutical companies in protecting their COVID-19 medicines from counterfeiting.
The initiative supports pharmaceutical companies and their suppliers with the free supply of tools for the use of Cryptoglyph on their packaging. The digital security feature can be implemented and used within a few weeks. become. Cryptoglyph is invisible to the human eye. A product protected with it is authenticated using a normal smartphone.
Securing packaging with Cryptoglyph is simple and requires no additional consumables as it does not interfere with standardised manufacturing processes. In addition, the applications on the smartphone connect to the Brand Monitoring System (BMS) from AlpVision, a centralised server platform via which pharmaceutical companies can Monitor product authentication activities in real time and gain important insights into counterfeiting activities.
The „AlpVision COVID-19 Initiative“ starts on 13 November 2020 and the first registration period will run for three months. Participating companies can protect their COVID-19 products without incurring additional costs for the authentication function. The anti-counterfeiting specialist wants to make this service free of charge until the World Health Organisation officially declares the pandemic over.
[infotext icon] Founded in 2001, AlpVision is a global leader in digital anti-counterfeiting technologies for product authentication and anti-counterfeiting protection. Its solutions are sold worldwide under licence agreements as fully customisable, turnkey computerised systems. The company currently provides protection for over 30 billion products every year[/infotext].SourceAlpvision
